Logo image of RPID

RAPID MICRO BIOSYSTEMS INC-A (RPID) Stock Fundamental Analysis

NASDAQ:RPID - Nasdaq - US75340L1044 - Common Stock - Currency: USD

3.68  +0.28 (+8.24%)

Fundamental Rating

2

Overall RPID gets a fundamental rating of 2 out of 10. We evaluated RPID against 54 industry peers in the Life Sciences Tools & Services industry. RPID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RPID is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RPID has reported negative net income.
In the past year RPID has reported a negative cash flow from operations.
RPID had negative earnings in each of the past 5 years.
In the past 5 years RPID always reported negative operating cash flow.
RPID Yearly Net Income VS EBIT VS OCF VS FCFRPID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RPID has a worse Return On Assets (-52.47%) than 83.33% of its industry peers.
RPID has a worse Return On Equity (-68.45%) than 74.07% of its industry peers.
Industry RankSector Rank
ROA -52.47%
ROE -68.45%
ROIC N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
RPID Yearly ROA, ROE, ROICRPID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

With a Gross Margin value of 6.13%, RPID is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
The Profit Margin and Operating Margin are not available for RPID so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 6.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPID Yearly Profit, Operating, Gross MarginsRPID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

RPID does not have a ROIC to compare to the WACC, probably because it is not profitable.
RPID has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RPID has been increased compared to 5 years ago.
Compared to 1 year ago, RPID has a worse debt to assets ratio.
RPID Yearly Shares OutstandingRPID Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPID Yearly Total Debt VS Total AssetsRPID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

RPID has an Altman-Z score of -4.21. This is a bad value and indicates that RPID is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.21, RPID is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
RPID has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
RPID has a Debt to Equity ratio of 0.00. This is in the better half of the industry: RPID outperforms 72.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.21
ROIC/WACCN/A
WACC10.45%
RPID Yearly LT Debt VS Equity VS FCFRPID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 4.61 indicates that RPID has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.61, RPID is doing good in the industry, outperforming 66.67% of the companies in the same industry.
A Quick Ratio of 3.23 indicates that RPID has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.23, RPID is doing good in the industry, outperforming 62.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.61
Quick Ratio 3.23
RPID Yearly Current Assets VS Current LiabilitesRPID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

RPID shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.88%, which is quite good.
RPID shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.34%.
Measured over the past years, RPID shows a quite strong growth in Revenue. The Revenue has been growing by 11.18% on average per year.
EPS 1Y (TTM)14.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
Revenue 1Y (TTM)28.34%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%28.41%

3.2 Future

Based on estimates for the next years, RPID will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.33% on average per year.
The Revenue is expected to grow by 19.18% on average over the next years. This is quite good.
EPS Next Y6.97%
EPS Next 2Y8.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year17.83%
Revenue Next 2Y19.18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RPID Yearly Revenue VS EstimatesRPID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
RPID Yearly EPS VS EstimatesRPID Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RPID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RPID. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPID Price Earnings VS Forward Price EarningsRPID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPID Per share dataRPID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.33%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RPID!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPID MICRO BIOSYSTEMS INC-A

NASDAQ:RPID (7/22/2025, 8:00:01 PM)

3.68

+0.28 (+8.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-01 2025-08-01/bmo
Inst Owners59.07%
Inst Owner Change0%
Ins Owners5.11%
Ins Owner Change24.16%
Market Cap161.29M
Analysts84.44
Price Target8.16 (121.74%)
Short Float %1.5%
Short Ratio4.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.91%
Min EPS beat(2)5.59%
Max EPS beat(2)6.22%
EPS beat(4)3
Avg EPS beat(4)2.27%
Min EPS beat(4)-2.76%
Max EPS beat(4)6.22%
EPS beat(8)6
Avg EPS beat(8)3.47%
EPS beat(12)8
Avg EPS beat(12)3.19%
EPS beat(16)8
Avg EPS beat(16)-303.44%
Revenue beat(2)2
Avg Revenue beat(2)5.16%
Min Revenue beat(2)3.29%
Max Revenue beat(2)7.03%
Revenue beat(4)4
Avg Revenue beat(4)8.07%
Min Revenue beat(4)3.29%
Max Revenue beat(4)13.82%
Revenue beat(8)8
Avg Revenue beat(8)7.5%
Revenue beat(12)10
Avg Revenue beat(12)6.22%
Revenue beat(16)12
Avg Revenue beat(16)2.86%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.44
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 2.46
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0.68
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.47%
ROE -68.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 6.13%
FCFM N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.3%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.61
Quick Ratio 3.23
Altman-Z -4.21
F-Score4
WACC10.45%
ROIC/WACCN/A
Cap/Depr(3y)112.45%
Cap/Depr(5y)118.7%
Cap/Sales(3y)17.47%
Cap/Sales(5y)14.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
EPS Next Y6.97%
EPS Next 2Y8.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)28.34%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%28.41%
Revenue Next Year17.83%
Revenue Next 2Y19.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.5%
OCF growth 3YN/A
OCF growth 5YN/A